Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ipsen
Ipsen
With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer
Fierce Pharma
Tue, 02/13/24 - 11:12 pm
Ipsen
Onivyde
Nalirifox
pancreatic cancer
FDA
Ipsen/Genfit eye June FDA verdict for liver drug elafibranor
Pharmaphorum
Thu, 12/7/23 - 11:01 am
Genfit
Ipsen
elafibranor
primary biliary cholangitis
FDA
priority review
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Tue, 11/14/23 - 09:20 am
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Mon, 08/21/23 - 10:02 am
Exelixis
Ipsen
Carbometyx
prostate cancer
FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease
BioSpace
Thu, 08/17/23 - 10:08 am
Ipsen
palovarotene
FDA
Sohonos
fibrodysplasia ossificans progressiva
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Fri, 06/30/23 - 10:12 am
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP
Globe Newswire
Wed, 06/28/23 - 10:27 pm
FDA
Ipsen
palovarotene
FOP
fibrodysplasia ossificans progressiva
FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm
BioSpace
Tue, 06/27/23 - 10:19 am
Ipsen
FDA
palovarotene
fibrodysplasia ossificans progressiva
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use
Fierce Pharma
Wed, 06/14/23 - 10:22 am
Ipsen
Bylvay
Albireo Pharma
M&A
FDA
liver disease
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Tue, 06/13/23 - 11:37 am
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Pfizer's fortunes overshadow first-quarter dealmaking
EP Vantage
Wed, 04/12/23 - 10:22 am
M&A
Pfizer
Seagen
Sanofi
Provention Bio
AstraZeneca
CinCor
Chiesi
Amryt
Ipsen
Albireo
FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on
Fierce Biotech
Sun, 03/19/23 - 01:34 pm
Ipsen
FDA
palovarotene
fibrodysplasia ossificans progressiva
Ipsen reports positive data from pancreatic ductal adenocarcinoma trial
Clinical Trials Arena
Mon, 01/23/23 - 10:53 am
Ipsen
Onivyde
metastatic pancreatic cancer
pancreatic cancer
clinical trials
Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial
Fierce Biotech
Thu, 01/19/23 - 10:03 am
Ipsen
IRLAB
clinical trials
Parkinson's Disease
mesdopetam
Biopharma’s bolt-on bonanza is set to continue
EP Vantage
Thu, 01/12/23 - 10:18 am
M&A
Amgen
AstraZeneca
Bristol Myers Squibb
GSK
Ipsen
Merck
Pfizer
Pages
1
2
3
4
next ›
last »